P4, N=76, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Jun 2026 --> Jan 2027

Anagrelide (ANA), α-interferon (IFN) and ruxolitinib (Ruxo) increased, while hydroxyurea (HU) decreased platelet size. Anagrelide-induced abnormalities are reverted by RANTES addition. RANTES plasmatic levels and platelet RNA expression are decreased in anagrelide-treated vs untreated patients, suggesting in vitro findings could reflect anagrelide action in vivo.

ET can also lead to PHT, portal vein thrombosis, and esophageal varices. Clinicians should consider these possibilities when dealing with such patients.

Our findings suggest that ropeginterferon alfa-2b could be considered as a second-line treatment option for patients with essential thrombocythaemia and leukocytosis.

P1, N=26, Active, not recruiting, Medical College of Wisconsin | Trial completion date: Oct 2025 --> Mar 2027

Discontinuation of hydroxyurea resolved symptoms permanently, and the patient was transitioned to ruxolitinib for management of the underlying disease. This case highlights the importance of recognizing hypersensitivity reactions during hydroxyurea therapy and implementing alternative strategies to optimize patient outcomes.

P4, N=50, Not yet recruiting, Emory University | Initiation date: Aug 2025 --> Dec 2025

An 87-year-old Japanese man was diagnosed with PV 22 years earlier and had been treated with hydroxyurea and aspirin. Leukemic evolution from MPNs often involves morphological changes in addition to genetic and chromosomal abnormalities. Therefore, during the follow-up of MPN, it is important to focus on changes in the blood cell morphology.

P2/3, N=8, Completed, Mazandaran University of Medical Sciences

In this respect, the catalytic activity of the Fe complexes of two PTSCs, Triapine (3AP) and Dp44mT, with the two most abundant reducing agents, ascorbate and glutathione, was evaluated under aerobic conditions...Thus, Fe-PTSC and Fe-PTSC2 are unlikely to drive ROS production through a direct mechanism. Instead, an indirect mechanism or a site-specific ROS production appears to be more plausible.

P1, N=26, Active, not recruiting, Medical College of Wisconsin | Recruiting --> Active, not recruiting

Furthermore, leukaemic SAMHD1 protein expression negatively correlated with overall survival in a cohort of FLA-treated refractory AML patients. Our findings suggest that the addition of HU improves the efficacy of FLA-based regimens and warrant clinical trials to test the safety and efficacy of this combination in patients with relapsed/refractory AML.